NCT04571970View on ClinicalTrials.gov

RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

May 9, 2023

Study Completion Date

May 23, 2024

Conditions
Mucopolysaccharidosis Type II (MPS II)
Interventions
GENETIC

RGX-121

Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette

Trial Locations (2)

94609

University of California San Francisco, Benioff Children's Hospital, Oakland

H4A 3J1

McGill University Heath Center, Montreal

All Listed Sponsors
lead

REGENXBIO Inc.

INDUSTRY

NCT04571970 - RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) | Biotech Hunter | Biotech Hunter